Processing...
Clinical Trials for Melanoma
Search
Search
There are 158 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
158 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–2), including heavily pretreated patients (HLA-A*02:01–positive patients generally expected to have received prior tebentafusp when available), are treated with NBM-BMX, an oral HDAC8-selective histone deacetylase inhibitor aimed at epigenetic modulation to promote tumor cell-cycle arrest and apoptosis. NBM-BMX is given as empty-stomach oral capsules twice daily in continuous 28-day cycles with dose escalation (100–400 mg BID) followed by expansion until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: Adults with unresectable or metastatic melanoma that has progressed after at least one prior systemic therapy including anti–PD-1 (ECOG 0–1; treated/stable brain metastases allowed) receive DOC1021 (dubodencel), a personalized autologous dendritic-cell vaccine made from mobilized peripheral blood cells and loaded with patient-specific tumor antigens (tumor lysate + amplified tumor mRNA) to induce Th1/cytotoxic T-cell responses, with peginterferon alfa-2a as an immune adjuvant. Treatment includes filgrastim mobilization with leukapheresis, two image-guided perinodal DOC1021 injections 2 weeks apart with 4 weeks of weekly peginterferon (optional 6‑month booster with additional peginterferon), and anti–PD-1 is held until ~6 weeks after the first DOC1021 dose (may be resumed later per protocol).
ClinicalTrials.gov ID: NCT07288112
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Adults with advanced measurable solid tumors who have exhausted or are ineligible for standard therapies, with a melanoma-focused expansion requiring known BRAF status and generally ≤3 prior systemic lines. All patients receive BI 3810944 monotherapy, an investigational small-molecule anticancer agent with undisclosed target/mechanism, given initially weekly then typically every 3 weeks.
ClinicalTrials.gov ID: NCT07224425
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic melanoma or advanced non-small-cell lung cancer who have progressed after at least anti-PD-1/PD-L1 therapy, using an autologous tumor-infiltrating lymphocyte product (IOV-4001) genetically edited to knock out PD-1 via TALEN technology, administered after lymphodepleting chemotherapy and followed by high-dose IL-2. PD-1 knockout aims to enhance TIL antitumor activity by reducing exhaustion.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: This study enrolls adults with unresectable, locally advanced, or metastatic antigen-rich solid tumors—including TMB-H, MSI-H/dMMR, virally associated, metastatic colorectal, triple negative breast, platinum-resistant ovarian, metastatic castration-resistant prostate, and NSCLC—who lack standard treatment options. Patients receive STAR0602 (invikafusp alfa), a bifunctional bispecific antibody that selectively activates and expands Vβ6/Vβ10 T cell subsets to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—such as NSCLC (KRAS non-G12C), melanoma (BRAF/NRAS), histiocytic neoplasms, thyroid carcinoma, colorectal carcinoma (BRAF Class II/III), or other BRAF-mutant tumors—who have exhausted standard therapies, to receive oral BDTX-4933, a brain-penetrant RAF/RAS clamp inhibitor targeting a range of RAS/MAPK pathway mutations. The study includes dose escalation and expansion phases to assess safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT05786924
TrialFetch AI summary: This trial enrolls adults with recurrent or metastatic GRPR-expressing solid tumors (including mCRPC, HR+/HER2- breast, colorectal, cervical, melanoma, and NSCLC) who have progressed on at least two prior systemic therapies, and treats them with 212Pb-DOTAM-GRPR1, a radiolabeled peptide that targets the gastrin-releasing peptide receptor (GRPR) to deliver alpha particle radiation directly to tumor cells.
ClinicalTrials.gov ID: NCT05283330